Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2
Евгения Валерьевна Безрукова, Илья Владимирович Духовлинов, Александр Митрофанович Ищенко, Александр Леонидович Кадыков, Александр Александрович Колобов, Александр Владимирович Петров, Андрей Семенович Симбирцев · 2018 · RU2672861C2 · patent family 56095723
Published 2018-11-20.
Reported patent results
Narrative findings; numerical extraction incomplete
Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.
Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pharyngitis example | Initial improvement followed by worsening the next day; no complaints by day 5 | One 27-year-old patient; the transient worsening is retained |
| Respiratory-illness example | Nasal discharge reportedly stopped and general condition improved by day 3 | Individual case; natural recovery and concurrent effects are not separated |
Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The later patent explicitly names gamma-D-glutamyl-L-tryptophan in combination with type I or III interferon.
This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.
- Publication
- RU2672861C2 ↗ · 2018-11-20
- Earliest priority / filing
- 2014-10-31 / 2014-10-31
- Original applicant / assignee
- Общество с ограниченной ответственностью "Эксифарм" (ООО "Эксифарм")
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 56095723 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Composition based on interferon i or iii type and gamma-d-glutaminyl-l-tryptophan for prevention and treatment of infectious diseases and immunodeficiency conditions (options)
Inventors: Евгения Валерьевна Безрукова; Илья Владимирович Духовлинов; Александр Митрофанович Ищенко; Александр Леонидович Кадыков; Александр Александрович Колобов; Александр Владимирович Петров; Андрей Семенович Симбирцев.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.
- Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-56095723. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Евгения Валерьевна Безрукова, Илья Владимирович Духовлинов, Александр Митрофанович Ищенко, Александр Леонидович Кадыков, Александр Александрович Колобов, Александр Владимирович Петров, Андрей Семенович Симбирцев. Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2 RU2672861C2 · patent family 56095723 2018.
Molekul research summary: https://molekul.io/research/patent-ru2672861c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry